Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment? Int J Mol Sci. 2021 Jun 26;22(13):6881
This review compiled previous studies surrounding treatment of schizophrenia using omega-3 and looked at what pathways in the brain are impacted by an omega-3 supplementation. After compiling information on omega-3 and anti-psychotic drugs it was found that the drugs used to treat schizophrenia and omega-3 supplementation impact on dopamine and glutamate transmission, oxidative stress, inflammation, myelination, and neurotransmission pathways in a similar way. Through evaluation of multiple clinical studies on omega-3 supplementation it was concluded that omega-3 has been linked to improved symptoms in those experiencing a schizophrenic episode. This research suggests that omega-3 supplementation may be an important consideration in schizophrenia.
To view the abstract, click here